21.5 C
New York
Tuesday, June 6, 2023

Is Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Regeneron Pharmaceuticals Inc. (REGN) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $798.45. The Regeneron Pharmaceuticals Inc. has recorded 10,047 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

Regeneron Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $798.45 and fluctuated between $815.24 as its day high and $796.52 as its day low. The current market capitalization of Regeneron Pharmaceuticals Inc. is $86.56B. A total of 0.61 million shares were traded on the day, compared to an average of 595.09K shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, REGN has seen 13 BUY and 76 SELL insider trades, representing the acquisition of 76,445 and the disposition of 106,178 shares. Over the last 12 months, there were 77 BUYs and 358 SELLs from insiders. Insiders purchased 458,868 shares during that period but sold 491,570.

In the most recent transaction, BROWN MICHAEL S sold 3,070 shares of REGN for 798.42 per share on Apr 21. After the transaction, the Director now owns 1,247 company shares. In a previous transaction on Apr 03, McCourt Marion sold 1,100 shares at 818.80 per share. REGN shares that EVP Commercial owns now total 20,803.

Among the insiders who sold shares, RYAN ARTHUR F disposed of 100 shares on Apr 03 at a per-share price of $819.31. This resulted in the Director holding 19,047 shares of REGN after the transaction. In another insider transaction, Landry Robert E sold 1,007 shares at $823.47 per share on Mar 28. Company shares held by the EVP Finance CFO now total 31,922.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for REGN in the last 3 months, the mean price target is $896.00 with high estimates of $1,050.00 and low estimates of $650.00. In terms of 52-week highs and lows, REGN has a high of $837.55 and a low of $538.01.

As of this writing, REGN has an earnings estimate of $9.6 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $10.95 per share and a lower estimate of $7.76. The company reported an EPS of $11.14 in the last quarter, which was 17.50% higher than expectations of $9.48.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. REGN’s latest balance sheet shows that the firm has $12.53B in Cash & Short Term Investments as of fiscal 2021. There were $2.70B in debt and $3.45B in liabilities at the time. Its Book Value Per Share was $212.21, while its Total Shareholder’s Equity was $18.77B.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 27 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for REGN is Sell with a score of 4.41. A total of 16 analysts rated the stock as Buy while 1 rated it as Overweight while 8 rated it as Hold. Among the other participants, 2 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles